USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Targeted Therapeutics and Immunology Combine to Take Colorectal Cancer Treatments to the Next Level
09-Sep-2015
North America
Market Research
M986-01-00-00-00
LS00095-NA-MR_16936
Research Overview
This Frost & Sullivan research service on the global colorectal cancer market provides in-depth analyses of industry trends, market shares, competitive analysis, market opportunities and revenue forecasts from 2014 to 2021. It also features a SWOT analysis of drugs that are available in the market as well as those under development. In this market research, Frost & Sullivan's expert analysts thoroughly examine the following modalities:
- targeted therapies
- cytotoxics
- cancer vaccines
- other products (bone calcium regulators, cytotoxic antibiotics, anti-cancer agents, immunostimulants, alkylating agents and anti-metabolites).
The evaluation of each drug class is supported by information on clinical trials, projected launch timelines, and epidemiology.
Market Overview
Strong drug pipeline continues to expand
The pipeline for colorectal cancer treatment boasts a vast number and variety of remedies. The high incidence of the disease, unmet treatment needs and their commercial potential attracts drug developers to the market. Advancements are centred on identifying new molecular targets and reducing toxicity. Several immunotherapies and cancer vaccines are being developed as pharmaceutical and biotech companies attempt to utilise the body's own immune system mechanism to attack tumours. Immune-based therapies will play a vital role in future cancer treatment as they can increase survival rates and overcome patients' resistance to existing therapeutics.
Colorectal cancer care edges toward personalisation
With the increasing focus on treatment outcomes, the market for colorectal cancer is undoubtedly moving toward personalised modes of care. Targeted solutions dominate the colorectal cancer pipeline, accounting for 60 percent of the treatment modalities under production. The improved understanding of the molecular mechanisms of colorectal cancer will facilitate the identification of newer targets and give rise to multi-targeted therapies. Meanwhile, biomarker testing is expected to become the standard of care, as it can help select a targeted therapy for a patient's particular need (predictive biomarkers), as well as define the patient's specific tumour type (prognostic biomarkers).
Beyond effective care delivery, employing targeted solutions will greatly enhance the reimbursement potential. By treating patients that are most likely to respond to a particular therapy, healthcare givers will be able to better justify the high costs to insurance firms and government payers. Therefore, clinical trials of targeted therapy drugs using biomarkers as surrogate endpoints will boost their chances of approval. Ultimately, the use of targeted remedies, coupled with immunotherapy, though complicated, will bridge the gap between the current need and future scope of colorectal cancer treatment globally.
Executive Summary
Executive Summary (continued)
Executive Summary (continued)
Executive Summary (continued)
Executive Summary (continued)
Physician Treatment Guidelines—Lines of Therapy
Key Trends
Market Opportunities
Companies to Watch
Methodology and Scope
Market Overview—Types of Treatment in Development
Market Overview—Global Incidences of CRC
Market Overview—US Incidence Rates by Year and Sex
Market Overview—Biomarker Type Segmentation
Market Overview—Key Mergers, Acquisitions, and Partnerships
Market Overview—Recent Developments
Global CRC Market—Revenue Forecast
Revenue Forecast Discussion
Revenue Forecast Discussion (continued)
Revenue Forecast Discussion (continued)
Competitive Landscape Overview
Competitive Landscape—Phase III to Launch
Competitive Landscape—Phase II
Competitive Landscape—Phase I
Key Marketed Products
Key Marketed Products (continued)
Key Marketed Products (continued)
Key Marketed Products (continued)
Pipeline Synopsis—Phase III
Pipeline Synopsis—Phase III (continued)
Pipeline Synopsis—Phase III (continued)
Pipeline Synopsis—Phase III (continued)
Pipeline Synopsis—Phase III (continued)
Pipeline Synopsis—Phase II
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase II (continued)
Pipeline Synopsis—Phase I
Pipeline Synopsis—Phase I (continued)
Pipeline Synopsis—Phase I (continued)
Pipeline Synopsis—Phase I (continued)
Pipeline Synopsis—Phase I (continued)
Pipeline Synopsis—Phase I (continued)
Competitive Landscape—Pivotal Phase III Trials
Timeline of Key Events
Patent Expirations
Pipeline Discussion
Pipeline Discussion (continued)
Product Dashboard: Avastin (Bevacizumab)—Genentech Inc. (Roche Group)
Avastin (Genentech, Roche)—SWOT Analysis
Product Dashboard—BBI503: Boston Biomedical
BBI503 (Boston Biomedical)—SWOT Analysis
Product Dashboard—Cyramza (ramicirumab): Eli Lilly
Cyramza (ramicirumab) (Eli Lilly)—SWOT Analysis
Product Dashboard—Erbitux (cetuximab): Eli Lilly/BMS/Merck
Erbitux (Eli Lilly, BMS, and Merck)—SWOT Analysis
Product Dashboard—Imprime PGG: Biothera
Imprime PGG (Biothera)—SWOT Analysis
Product Dashboard—Lonsurf (TAS-102): Taiho (Otsuka)
Lonsurf (TAS–102) (Taiho, Otsuka)—SWOT Analysis
Product Dashboard—MGN1703: Mologen
MGN1703 (Mologen)—SWOT Analysis
Product Dashboard—Nintedanib (BIBF-1120, OFEV): Boehringer Ingelheim
Nintedanib (BIBF–1120, OFEV) (BI)—SWOT Analysis
Product Dashboard—Stivarga (regorafenib): Bayer/Onyx Pharmaceuticals
Stivarga (Bayer, Onyx)—SWOT Analysis
Product Dashboard—Zaltrap (aflibercept): Sanofi
Zaltrap (aflibercept) (Sanofi)—SWOT Analysis
Conclusions
Conclusions (continued)
The Last Word—3 Big Predictions
The Last Word—Discussion
Legal Disclaimer
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Barbara Gilmore |
| WIP Number | M986-01-00-00-00 |
| Keyword 1 | Global Colorectal Cancer |
| Keyword 2 | Colorectal Cancer |
| Keyword 3 | Pipeline Analysis of the Colorectal Cancer |
| Is Prebook | No |
Product and Pipeline Analysis of the Global Colorectal Cancer Market
$3,950.00
Special Price $2,962.50 save 25 %